Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Nationwide study questions routine long-term beta-blocker post MI

Key clinical point: Current guideline recommendations for long-term beta-blocker therapy after an acute MI may be outdated in the contemporary reperfusion era.

Major finding: At 3 years post MI, the major adverse cardiovascular event rate was 22.9% in patients on long-term beta-blocker therapy group and not significantly different at 21.6% in those who were not.

Study details: This was an observational Danish national registry study of more than 30,000 optimally treated patients with a first MI during 2003-2018.

Disclosures: The presenter reported having no financial conflicts regarding his study, conducted free of commercial support.

Citation:

Holt A. ESC 2020.